Kyungdong Pharmaceutical Co., Ltd.

Quick facts

Phase 3 pipeline

• KDF1901
  KDF1901 is an investigational therapeutic agent in phase 3 development by Kyungdong Pharmaceutical, but its specific mechanism of action has not been publicly disclosed.
• KDF1901-L · Diabetes
  KDF1901-L is a small molecule that targets the SGLT2 receptor.
• KDF1901-R0 · Diabetes
  KDF1901-R0 is a small molecule that targets the SGLT2 receptor.
• KDF1901-R1 · Diabetes
  KDF1901-R1 is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kyungdong Pharmaceutical Co., Ltd. portfolio CI brief
• Kyungdong Pharmaceutical Co., Ltd. pipeline updates RSS